Hims & Hers Health (NYSE:HIMS) is gearing up to launch an off-patent version of Novo Nordisk's (NVO) (OTCPK:NONOF) older GLP-1 weight loss therapy liraglutide in 2025, CEO of the telehealth platform ...

Hims Hers Health Inc (NYSE:HIMS) reported third-quarter earnings that surpassed analyst expectations and raised its full-year ...

Americans are still eagerly seeking prescriptions for Eli Lilly and Novo Nordisk’s weight-loss and diabetes drugs but cannot ...

Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...

Hims & Hers Health, Inc. ( (HIMS) ) has released its Q3 earnings. Here is a breakdown of the information Hims & Hers Health, Inc.

Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy ...

Reports Q3 revenue $401.6M, consensus $382.2M. “Improving momentum in both the Hims and Hers brands delivered another strong quarter of ...

The U.S. stock market experienced a slight downturn on Monday, with the S&P 500 index dipping approximately 0.3%. The Dow ...

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

Hims offers brand-name semaglutide prescriptions like Wegovy and unbranded compounded semaglutide, which tends to be much ...

Hims & Hers Health raised its full-year outlook after it swung to a profit in the third quarter boosted by a tax benefit and consumer demand for weight-loss drugs.